Featured product: Angio-Seal™ VIP Vascular Closure Device
Resnic FS, et al. A cost-minimization analysis of the Angio-Seal vascular closure device following percutaneous coronary intervention (PCI). Am J Cardiol. 2007;99(6):766-70.DESCRIPTIONObjective: Explore the health economic implications of routinely using the Angio-Seal vascular closure device after PCI
The hospital realized a net cost savings of $44 for each study patient who received an Angio-Seal device over those treated with mechanical compression
The economic benefit of the Angio-Seal device reflected the higher rate of access site bleeding and pseudoaneurysm in the mechanical compression group
Cost of vascular complications can ranged from $1.399 for a hematoma to $6.698 for a retroperitoneal hemorrhage.
A sensitivity analysis found that the cost of compression would have to drop below $66 to become more cost-effective than the Angio-Seal device
Jun Jiang et al. Network Meta-analysis of Randomised Trials on the Safety of Vascular Closure Devices for Femoral Arterial Puncture Site Haemostasis. Sci Rep.; 5:13761. 2015.
DESCRIPTIONObjective: Network meta-analysis comparing the safety of different VCDs.
Traditional meta-analysis: risk for CAVE is similar between VCDs and MC
Subgroup analysis: similar results, but FemoSeal showed significantly reduced risk of CAVE
Haematoma risk: significantly lower with VCDs vs MC (RR: 0.80, CI: 0.71-0.90)
Design improvements of VCDs & increased user experience -> decreases risk of CAVE
Vascular closure devices
N° of studies
Test for overal effect
RR (95% CI)
0.69 [0.46, 1.03]
1.10 [0.75, 1.61]
1.45 [0.55, 3.84]
1.27 [0.48, 3.37]
0.75 [0.60, 0.94]
1.00 [0.65, 1.52]
0.63 [0.29, 1.37]
*Statistically significant.2. Network analysis on CAVE:
Angio-Seal – reduced risk of CAVE vs MC (RR: 0.67, CI: 0.46–0.98)
Other VCDs: similar risk for CAVE vs MC. No difference in risk for CAVE between different VCDs.
The use of VCDs significantly decreased the risk of haematomas
The newly developed VCDs significantly reduced the rate of CAVE
FemoSeal also significantly reduced the risk of CAVE. Newer VCDs with advanced design might improve the safety of VCDs
Angio-Seal, which might be the best VCD among all included VCDs, reduced the rate of both CAVE and haematomas vs MC
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.